138 related articles for article (PubMed ID: 36937234)
1. Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report.
Verhaert M; Mebis J; Aspeslagh S; von Kemp B
Eur Heart J Case Rep; 2023 Mar; 7(3):ytad112. PubMed ID: 36937234
[TBL] [Abstract][Full Text] [Related]
2. Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report.
Moriyama S; Fukata M; Tatsumoto R; Kono M
Eur Heart J Case Rep; 2021 Jan; 5(1):ytab002. PubMed ID: 33644656
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor Induced Pericarditis and Encephalitis in a Patient Treated With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report and Review of the Literature.
Braden J; Lee JH
Front Oncol; 2021; 11():749834. PubMed ID: 34956874
[TBL] [Abstract][Full Text] [Related]
4. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Heinzerling L; Ott PA; Hodi FS; Husain AN; Tajmir-Riahi A; Tawbi H; Pauschinger M; Gajewski TF; Lipson EJ; Luke JJ
J Immunother Cancer; 2016; 4():50. PubMed ID: 27532025
[TBL] [Abstract][Full Text] [Related]
6. Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report.
Dang H; Sun J; Wang G; Renner G; Layfield L; Hilli J
World J Clin Cases; 2020 Sep; 8(18):4100-4108. PubMed ID: 33024767
[TBL] [Abstract][Full Text] [Related]
7. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
[TBL] [Abstract][Full Text] [Related]
8. An unusual case of checkpoint-inhibitor-induced pleuropericarditis.
Suarez ZK; Finke AC; Hospedales E; Perez E; Sharifzadeh A; Foster J; Ferris A
J Oncol Pharm Pract; 2023 Sep; 29(6):1525-1528. PubMed ID: 37254508
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option.
Greene A; Penner S; Kunesh J; Altaf A; McGrade W; Niu J
J Oncol Pharm Pract; 2024 Mar; ():10781552241241493. PubMed ID: 38544442
[TBL] [Abstract][Full Text] [Related]
10. Rechallenging nivolumab following immune checkpoint inhibitor-induced pericarditis.
Ali MR; Darwish OJ; Alhuneafat L; Abdallah BN; Saleh Y
Proc (Bayl Univ Med Cent); 2023; 36(1):83-84. PubMed ID: 36578622
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.
Siciliano MA; Dastoli S; d'Apolito M; Staropoli N; Tassone P; Tagliaferri P; Barbieri V
Front Oncol; 2020; 10():579445. PubMed ID: 33163407
[TBL] [Abstract][Full Text] [Related]
13. Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report.
Norwood TG; Wang MJ; Huh WK
Gynecol Oncol Rep; 2019 Nov; 30():100508. PubMed ID: 31737773
[TBL] [Abstract][Full Text] [Related]
14. Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series.
Chye AM; Nordman IIC; Sverdlov AL
Front Cardiovasc Med; 2022; 9():964324. PubMed ID: 36017099
[TBL] [Abstract][Full Text] [Related]
15. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
[TBL] [Abstract][Full Text] [Related]
16. The impact of corticosteroid use during anti-PD1 treatment.
Pan EY; Merl MY; Lin K
J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
[TBL] [Abstract][Full Text] [Related]
17. A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer.
Machida M; Yamazaki C; Kouda N; Hanai Y; Sato H; Konda A; Yamagata Y; Itho T; Aisaka H
J Pharm Health Care Sci; 2022 Dec; 8(1):29. PubMed ID: 36464708
[TBL] [Abstract][Full Text] [Related]
18. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
19. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
20. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.
Vandepapelière J; Siplet J; Libbrecht L; Dano H; Baurain JF; Moreels T
Acta Gastroenterol Belg; 2020; 83(3):482-484. PubMed ID: 33094598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
